Liver injury draft guidance update
Executive Summary
FDA re-opens the comment period for the draft guidance "Drug-Induced Liver Injury: Premarketing Clinical Evaluation" until June 30. In addition, a public meeting to discuss the draft will be held March 26 and 27. Meeting topics include whether patients with stable chronic liver disease should be included in clinical trials. FDA recommends in the draft guidance that firms enroll patients with pre-existing liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients. In comments submitted by the original closing date of Dec. 24, industry requested more clarification on how such patients should be included (1"The Pink Sheet," Feb. 18, 2008, p. 21)
You may also be interested in...
Pharma Seeks More Guidance On Drug-Induced Liver Injury
Although major pharmaceutical companies do not appear to be rejecting the proposal in FDA's draft guidance on drug-induced liver injury that trials enroll patients with preexisting liver disease, according to comments submitted on the draft, the companies would like to see more clarification on how such patients should be included
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.